Concordantly, in a phase 1 trial on cirmtuzumab, a monoclonal antibody directed against ROR1, gene expression signatures associated with stemness were markedly lower in post-treatment samples of CLL patients [112]. Here, ROR1 is linked to B-cell chronic lymphocytic leukemia.